Summary of clinical data for Hb-SS subjects
| . | TRV 2.5 m/s or over (n = 17) . | TRV under 2.5 m/s (n = 23) . | P . |
|---|---|---|---|
| Age, y (± SD) | 35.1 (± 13.2) | 29.6 (± 8.3) | .14 |
| Female, % | 71 | 52 | .24 |
| WHO/NYHA Class, % | — | ||
| I | 52.9 | 60.9 | .09 |
| II | 17.7 | 34.8 | — |
| III | 29.4 | 4.4 | — |
| TRV, m/s (± SD) | 2.59 (± 0.29) | 1.98 (± 0.21) | <.001 |
| Hydroxyurea use, % | 35.3 | 34.8 | .97 |
| . | TRV 2.5 m/s or over (n = 17) . | TRV under 2.5 m/s (n = 23) . | P . |
|---|---|---|---|
| Age, y (± SD) | 35.1 (± 13.2) | 29.6 (± 8.3) | .14 |
| Female, % | 71 | 52 | .24 |
| WHO/NYHA Class, % | — | ||
| I | 52.9 | 60.9 | .09 |
| II | 17.7 | 34.8 | — |
| III | 29.4 | 4.4 | — |
| TRV, m/s (± SD) | 2.59 (± 0.29) | 1.98 (± 0.21) | <.001 |
| Hydroxyurea use, % | 35.3 | 34.8 | .97 |
WHO/NYHA indicates World Health Organization/New York Heart Association; and —, not applicable.